Stem cell transplant is used as a treatment of last resort in young patients with acute lymphoblastic leukaemia (ALL) whose disease has failed to respond to or relapsed after chemotherapy. Only half of patients undergoing transplant are cured long-term, and disease relapse is the major cause of treatment failure. Professor Amrolia is pioneering the development of a new immunotherapy approach to treat relapsed ALL. If successful, this should not only improve survival but also reduce toxicity and improve quality of life for children with this disease.
This research project on acute lymphoblastic leukaemia has been successfully completed. Your donations allow us to fund ground-breaking research that can improve treatments given to children with cancer. Thank you. Your help allows us to continue to find ways to drive up the chances of survival for children with cancer and reduce the toxic side effects that can affect the rest of their lives.
Immunotherapy for relapsed paediatric acute lymphoblastic leukaemia
Professor Persis Amrolia
UCL Institute of Child Health, London
London WC1N 1EH
19 January 2015
I’m delighted to say we’ve now completed treatment for our initial group of patients and the outcomes have been very promising. Without the support of Children with Cancer UK, these children would not have had access to this ground-breaking new treatment over the last two and a half years. I am very grateful to you all.Professor Persis Amrolia October 2019 Read more about the clinical trial